Related Experiment Video
Updated: Jun 6, 2026

A Point-of-Care Method with Integrated Decision Support Tool to Estimate Anemia at Population Level
Published on: January 19, 2024
Diphenylhydantoin-induced severe yet reversible anemia during pregnancy
Akinori Sugaya1, Kiyotaka Nakamagoe, Yasushi Okoshi
1Department of Neurology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan.
Abstract:
Diphenylhydantoin (DPH) therapy, often used in treating epileptic seizures, can cause anemia in some patients. A 26-year-old female suffered from convulsions due to encephalitis and was placed on DPH therapy. About two months after the initiation of DPH therapy, her hemoglobin level was 3.8 g/dL. Her anemia improved after the discontinuation of DPH, confirming that the anemia was caused by DPH. Pure red-cell aplasia (PRCA) combined with hemolytic anemia was indicated by results such as erythroid aplasia, an increased LDH level, and a decreased haptoglobin level. PRCA complicated by hemolytic anemia could be responsible for anemia associated with DPH.
Related Concept Videos
Vitamins
Teratogenicity
Hemodialysis II: Procedure and Complications
Drug Toxicity: Dose-Dependent Reactions
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug toxicity: Idiosyncratic Reactions
